Heliad Announces Full Year 2024 Financial Results

Heliad (ETR:A7A) Full Year 2024 Financial Results

Highlight Financial Metrics

Revenue: €6.58m (a 55% increase compared to FY 2023).

Net income: €2.75m (an improvement from a €15.6m loss in FY 2023).

Profit margin: 42% (up from a net loss in FY 2023). The shift to profitability was mainly due to reduced expenses.

Could this be the end of cancer? These 15 innovative AI stocks are working on technologies that enable early detection of significant diseases, including cancer and Alzheimer’s.

All figures displayed in the chart above reflect the trailing 12-month (TTM) period.

Heliad’s stock has risen by 3.1% over the past week.

Risk Assessment

It remains crucial to acknowledge the ever-present risk associated with investments. We have identified 1 warning sign related to Heliad, and it is important to consider this in your investment strategy.

Do you have feedback on this article? Concerns about the content? Contact us directly. Alternatively, reach out to editorial-team (at) simplywallst.com.

This article from Simply Wall St is of a general nature. Our commentary is based on historical data and analyst forecasts using an unbiased approach; thus, it should not be construed as financial advice. It is not a recommendation for buying or selling any stock, nor does it consider your specific objectives or financial circumstances. We strive to provide long-term analysis based on fundamental data. Please note that our analysis may not incorporate the most recent price-sensitive company announcements or qualitative aspects. Simply Wall St holds no positions in any stocks mentioned.